Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase II Multi-Center Evaluation to Assess the Safety and Tolerability of DM199 Administered Intravenously and Subcutaneously in Subjects With Acute Ischemic Stroke

NCT03290560 is registered in ClinicalTrials.gov with DiaMedica Therapeutics Inc as lead sponsor.

NCT NCT03290560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03290560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase II Multi-Center Evaluation to Assess the Safety and Tolerability of DM199 Administered Intravenously and Subcutaneously in Subjects With Acute Ischemic Stroke
Lead sponsor
DiaMedica Therapeutics Inc
Phase
Phase 2
Overall status
Completed
Start date
January 19, 2018
Completion date
January 23, 2020
Enrollment
92 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke